Awarded
2 - L2_LENVATINIB (DOE) indicado para el tratamiento de carcinoma diferenciado de tiroides, para el tratamiento de carcinoma hepatocelular y para el t
Original language: Spanish
Track this recordWith Adjudera Pro, get alerted before a contract here runs out.
- Winners
- EISAI FARMACEUTICA, S.A.
- Contract value
- €753,132
- Bids received
- 1
- Published
- 15 Apr 2025
- Awarded
- 11 Apr 2025
- Contract start
- 12 Apr 2025
- Contract end
- 11 Apr 2026stated
- Region
- Araba/Álava